Actively Recruiting
Evaluating the Effects of Usnoflast on Amyotrophic Lateral Sclerosis in Adults A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study with Open-Label Extension
Led by Zydus Therapeutics Inc. · Updated on 2026-09-01
240
Participants Needed
49
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating Usnoflast in adults with Amyotrophic Lateral Sclerosis ALS to study its effects on disease progression, safety, and how the drug works in the body. This phase 2b trial is randomized, double-blind, placebo-controlled, and parallel-group across multiple centers, aiming to assess Usnoflasts efficacy and safety over 36 weeks, followed by an open-label extension. The study addresses the urgent need for new treatments for ALS, a progressive neuromuscular disease. Participants receive either 50 mg or 75 mg doses of Usnoflast or matching placebo capsules twice daily under fasting conditions for 36 weeks. After this period, eligible participants from all groups can join a 16-week open-label extension where everyone receives 75 mg Usnoflast twice daily. This extension helps confirm the long-term safety and effectiveness of Usnoflast. During the study, participants will be regularly assessed for motor function using the ALS Functional Rating Scale-Revised, survival rates, lung function, and biomarkers in blood and cerebrospinal fluid. Researchers will monitor drug levels in plasma and cerebrospinal fluid at specific times after dosing. Safety will be carefully tracked, including any adverse events. The total participation can last up to 52 weeks, including the treatment and extension phases.
CONDITIONS
Brief Title
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Research Team
F
Farheen Shaikh
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here